Opus Genetics Inc (IRD)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$3.67+0.55%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put IRD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Improve earnings performance and reduce net losses: Comparison needs review.
View ThesisRevenue is contracting — down about 36% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 49% in its worst 12-month stretch.
View RiskIRD’s bet rests on managing capital to fund operations into 2029, despite weak financial performance and unprofitability. Q2 FY2026 revenue fell 72.4% year over year, and reported EPS was inline. IRD trades at 41× sales versus the 10× peer median. The price reflects less growth than our forecast, despite that premium. Our model puts the next-quarter miss probability near 54%. The capital-funding objective is threatened by a major fund’s share sale. Peer multiples imply a price about 4.3% below where it trades. The thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-30. IRD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering IRD (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for IRD in the last 4 months.
Continue this research
Compare IRD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IRD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across our valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No fair value published
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
This applies to all three horizons. The trailing multiples, peer comparison, and quality and trajectory reads on this page are unaffected. Names move in and out of this state day to day as the methods converge or diverge. Method agreement on this name is low.
Bottom 25% on quality vs scored peers
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put IRD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Secure and manage capital to fund operations into 2029
Capital management may be impacted by stock sale.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $3.67
The last 12 months of price, then the range of analyst 12-month targets from today’s $3.67.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Deliver clinical data readouts and scientific updates
Study success supports clinical data readouts objective.
Advances: Deliver clinical data readouts and scientific updates
Topline results support clinical data readouts objective.
Advances: Deliver clinical data readouts and scientific updates
Price target increase indicates positive clinical data expectations.
Advances: Deliver clinical data readouts and scientific updates
Positive share movement indicates investor confidence in upcoming trial data.
